1stOncology™: Cancer Intelligence Service – Page 13342 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

On September 4, 2019 Sutro Biopharma, Inc. (NASDAQ: STRO) reported that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, Sept. 10, 2019, at 11:40 AM EDT, in New York City (Press release, Sutro Biopharma, SEP 4, 2019, View Source [SID1234539264]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.sutrobio.com. A replay of the webcast will be available for approximately 30 days following the event.

Repare Therapeutics Announces US$82.5 Million Series B Financing

On September 4, 2019 Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, reported the completion of a US$82.5 million Series B financing (Press release, Repare Therapeutics, SEP 4, 2019, View Source [SID1234539263]).

Cowen Healthcare Investments led the financing and was joined by new investors OrbiMed, Redmile, BVF Partners L.P. and Logos Capital. Founding investor Versant Ventures and existing investors MPM Capital, Fonds de solidarité FTQ, and BDC Capital all participated.

Including today’s Series B financing and the June 2017 Series A round co-led by Versant and MPM, Repare has now secured over US$140 million in equity and partner capital.

"We are pleased to include this exceptional group of new investors along with our strong existing group of shareholders to continue building Repare’s leading position in synthetic lethality and DNA damage repair precision oncology treatments," said Lloyd M. Segal, President and Chief Executive Officer of Repare.

The core concept of synthetic lethality is that while tumors can tolerate individual defects in DNA, there are combinations of defects that create unique vulnerabilities in cancer cells which, when identified, present opportunities for precisely targeted therapeutics. Repare will use the proceeds of this financing to advance RP-3500, an ATR inhibitor, into the clinic in 2020. Repare will also advance an additional program, "Manchester", an undisclosed CCNE1 synthetic lethal targeted therapy, in the subsequent two to three quarters, and will continue to progress its deep pipeline of synthetic lethal, DNA damage repair programs, including its Polθ program, which was recently partnered with ONO Pharmaceutical Co., Ltd. in Japan and selected territories in Asia.

In connection with this investment, Kevin Raidy, Managing Partner, Cowen Healthcare Investments, and David Bonita, M.D., Partner, OrbiMed, will join Repare’s Board of Directors.

"We are confident in Repare’s exceptional management team and are excited by the potential of the company’s lead asset and innovative pipeline to advance treatments for targeted patient populations in multiple cancer indications," said Mr. Raidy.

"We feel that Repare is differentiated and highly enabled. Synthetic lethality and DNA damage repair remain critical domains for novel precision oncology and we believe that Repare has established itself as the leader in this field," noted Dr. Bonita.

Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

On September 4, 2019 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported a late-breaker poster presentation at the upcoming 17th International Myeloma Workshop being held in Boston, Massachusetts from September 12-15, 2019 (Press release, Cellectar Biosciences, SEP 4, 2019, View Source [SID1234539262]). The data will focus on the activity of CLR 131 in a Phase 1, dose escalation study of patients with relapsed or refractory multiple myeloma.

Late-Breaker poster presentation details

Poster Title: SP-305 CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Session: Poster Session II
Date/Time: Saturday September 14, 2019 / 7:00am to 5:45pm
Location: Hynes Convention Center Hall C Level II

A copy of the presentation materials can be accessed on the Posters and Publications section of the Cellectar website once the presentation concludes.

Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

On September 4, 2019 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, reported that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock") (Press release, Avid Bioservices, SEP 4, 2019, View Source [SID1234539260]).

The quarterly dividend on the Series E Preferred Stock is payable on October 1, 2019 to holders of record at the close of business on September 16, 2019.

The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from July 1, 2019 through September 30, 2019. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "CDMOP".

ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019

On September 4, 2019 ImaginAb Inc., a clinical-stage immuno-oncology imaging company, reported that it is scheduled to attend and / or present at the following investor and scientific conferences in September and October 2019 (Press release, ImaginAb, SEP 4, 2019, View Source [SID1234539259]).

World Molecular Imaging Congress 2019

September 4-7, 2019, Palais des congrès de Montréal, Montréal, Canada

Dr. Anna Wu, Ph.D., Founder and Chief Scientific Officer, will be attending and hosting meetings.

ESMO Congress 2019

September 27 – 1 October, 2019, Fira Gran Via, Barcelona, Spain

Dr. Anna Wu and Dr Toni Ribas, Ph.D., ImaginAb Science Advisory Board Member and President-Elect for The American Association for Cancer Research (AACR) (Free AACR Whitepaper), will be attending and hosting meetings. In addition, ImaginAb’s commercial team led by Ivan Plavec, Chief Business Officer (CBO), will be hosting meetings and available at the ImaginAb Booth #477.

Cavendish Global Conference: The 2019 Phoenix BioHealth Impact Forum

October 2-3, 2019, University Of Arizona – Phoenix Biomedical Campus, Phoenix, AZ, USA

Ian Wilson, CEO, will be attending and hosting meetings.

2nd Annual Advances in Immuno-Oncology USA Congress

October 8-9, 2019, DoubleTree by Hilton Hotel, San Diego, CA, USA

Ian Wilson, CEO, will be chairing a Panel Discussion on ‘Technological Challenges In Clinical Studies’ on October 9 at 13.30 PDT, Room 4.

Ian Wilson will also be presenting a session on ‘Insights on Reverse Translation for Patient Stratification in Clinical Studies’ on October 9 at 16.30 PDT, Room 4.

This follows CBO Ivan Plavec’s Pre-Congress Webinar on August 29, 2019, entitled ‘How CD8 Imaging Is Useful To Pharma Regarding Drug Research And Clinical Decision Making’ which is available to download here.

Optimum 11th Annual Healthcare Investor Conference

October 17, 2019, Bloomberg Headquarters, 3 Queen Victoria St, London, UK

Ian Wilson, CEO, will be attending and hosting meetings along with ImaginAb Board Director and Non-Executive Director at NICE, Tim Irish.

For further information please contact:

ImaginAb

Ian Wilson, Salli Walker
Email: [email protected]
Phone: +1 310 645 1211

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Manel Mateus
Email: [email protected]
Phone: +44 20 3950 9144